Mymetics’ HIV vaccine candidate confirms promise in preclinical study with the Texas Biomedical Research Institute

Epalinges, April 11 2016

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.

Media Name Media Type Description Download
160411 HIV_Mymetics-Texas Biomed PDF Download